Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics
  • Sandoz gains rights to three established brands sold in more than 100 markets
  • Transaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading position in cephalosporins
  • Acquisition confirms Sandoz commitment to antibiotics, following announcement of further investment plans for European-based manufacturing network

Basel, October 11, 2021 – Sandoz, a Novartis division, has successfully completed the acquisition of GSK’s cephalosporin antibiotics business.

Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs
  • Company previously disclosed settlement agreement in principle and fully provisioned for this resolution

Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement agreement with the Civil Division of the U.S. Department of Justice (DOJ) concerning the Department’s years-long pricing investigation into the U.S. generic drug industry. This settlement is an expected outcome of the resolution the company reached in March 2020 with the DOJ Antitrust Division regarding the same investigation and underlying conduct. Today’s …

Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
  • Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2
  • Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access, while contributing to sustainability of healthcare systems

Basel, September 8, 2021 — Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera …

Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.

Ad hoc announcement pursuant to Art. 53 LR

  • Net sales in Q2 grew +9% (cc¹, +14% USD):
    • Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21% cc) and Zolgensma (+48% cc). Kesimpta sales reached USD 66 million
    • Oncology BU grew +7% (cc, +11% USD) driven by Promacta/Revolade (+18% cc), Jakavi (+19% cc), Kisqali (+36% cc) and Tafinlar + Mekinist (+10% cc)
    • Sandoz grew +5 …
Sandoz launches first generic high dose intravenous iron, Ferumoxytol Injection, to treat US patients with iron deficiency anemia
  • Patients with iron deficiency anemia in a hospital or clinic setting now have access to an important IV iron medicine at a more affordable price
  • Iron deficiency anemia occurs when there is a lower than normal number of oxygen-carrying red blood cells because of too little iron1
  • Immediate availability of Ferumoxytol Injection bolsters Sandoz portfolio and delivers another high-quality generic medicine to US patients

Princeton, New Jersey, July 16, 2021 — Sandoz, a global leader in generic and biosimilar medicines …

Sandoz announces EU launch of ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer
  • Pemetrexed is indicated for patients with non-squamous Non-Small Cell Lung Cancer (NSCLC), who represent over 3 in 4 patients with lung cancer1
  • New ready-to-dilute format and 1,000 mg strength option helps avoid unnecessary handling steps to reduce associated contamination risks and patient waiting times2
  • The Pemetrexed launch will expand the Sandoz hospital portfolio in key European markets, strengthening access to treatment options for patients

Basel, June 25, 2021 — Sandoz today announced …

Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe
  • Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs
     
  • Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients
     
  • Investment affirms long-term confidence in antibiotics strategy, delivering and building on published plans for European-based manufacturing network

Basel, May 18, 2021 — Sandoz, a Novartis …

US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case
  • Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients
     
  • Sandoz is disappointed US patients affected by chronic autoimmune and inflammatory disease have to wait until 2029 for availability of biosimilar Erelzi
     
  • Sandoz remains committed to pioneering access for patients and contributing to more sustainable …
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
  • Sandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study1
  • Neovascular age-related macular degeneration accounts for 10% of age-related macular degeneration cases, but is responsible for 90% of AMD-related blindness2
  • With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems
     

Holzkirchen, …

Sandoz in-licenses brand and authorized generic of respiratory medicine Proventil® HFA (albuterol sulfate) Inhalation Aerosol from Kindeva Drug Delivery, with immediate generic availability in US
  • Albuterol sulfate is used to treat or prevent bronchospasm in patients four years and older with reversible obstructive airway disease, such as asthma, and to prevent exercise-induced bronchospasm1 
  • Immediate launch of our authorized generic will help ensure a reliable supply of albuterol medicines, as respiratory products see increased demand over past year 
  • Deal allows Sandoz to further grow respiratory portfolio and availability of our authorized generic ensures patients have access to an important medicine at an affordable price

Princeton, …